Lung cancer is the second most common human malignant disease and the leading cause of cancer-related mortality worldwide. The effect of CYP1A1 IleVal polymorphism on susceptibility to lung cancer has been researched extensively over the last two decades. However, controversial results were obtained. To provide a more robust estimate of the effect, a meta-analysis was carried out. We systematically searched the PubMed database for studies published before August 2010, without language restriction. On the basis of our search criteria, a total of 32 studies (5126 patients and 6974 controls) were included in the meta-analysis. Overall, CYP1A1 IleVal polymorphism is associated with lung cancer risk (GG vs. AG+AA: odds ratio=1.61, 95% confidence interval: 1.19-2.17; GG vs. AA: odds ratio=1.70, 95% confidence interval: 1.23-2.35). Ethnic subgroup analyses showed that a significant association was found in Asians, but not in Africans, Caucasians, or other populations. In subgroup analyses by histology, the result is not reliable. In conclusion, this meta-analysis suggests that the CYP1A1 IleVal polymorphism might play a modest role in susceptibility to lung cancer, especially in Asians.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0b013e328345f937DOI Listing

Publication Analysis

Top Keywords

lung cancer
20
susceptibility lung
12
cyp1a1 ileval
12
ileval polymorphism
12
polymorphism susceptibility
8
95% confidence
8
confidence interval
8
subgroup analyses
8
lung
5
cancer
5

Similar Publications

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.

J Natl Cancer Inst

January 2025

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Purpose: Overlapping genes are involved with rheumatoid arthritis (RA) and DNA repair pathways. Therefore, we hypothesised that patients with a high polygenic risk score (PRS) for RA will have an increased risk of radiotherapy (RT) toxicity given the involvement of DNA repair.

Methods: Primary analysis was performed on 1494 prostate cancer, 483 lung cancer and 1820 breast cancer patients assessed for development of RT toxicity in the REQUITE study.

View Article and Find Full Text PDF

Objective: This study aimed to evaluate the possibility of defining new imaging criteria to predict less-invasive clinical (c)-stage IA2-IA3 solid predominant lung adenocarcinoma using the maximum standardized uptake value (SUVmax) as the cutoff value.

Methods: Consecutive 364 patients who underwent anatomical resection with mediastinal lymphadenectomy and positron emission tomography for c-stage IA2-IA3 solid predominant lung adenocarcinoma with a tumor diameter < 3 cm were retrospectively evaluated. Less-invasive cancer was defined as the absence of nodal involvement, lymphovascular or pleural invasion, or spread through air spaces.

View Article and Find Full Text PDF

Purpose: To explore the dynamic and parametric characteristics of [F]F-FAPI-42 PET/CT in lung cancers.

Methods: Nineteen participants with newly diagnosed lung cancer underwent 60-min dynamic [F]F-FAPI-42 PET/CT. Time-activity curves (TAC) were generated for tumors and normal organs, with kinetic parameters (K, K, K, K, K) calculated.

View Article and Find Full Text PDF

In the preliminary screening, falcarinol and falcarindiol, C polyacetylenes from the roots of Glehnia littoralis F. Schmidt ex Miq (Umbelliferae), displayed cytotoxic activity both against oxaliplatin-sensitive/resistant colorectal cancer (CRC) and gefitinib-sensitive/resistant non-small cell lung cancer (NSCLC) cells. In this study, 13 polyacetylenes including a new (3R,11R)-11-hyroxy-isofalcarinolone (1) were isolated from G.

View Article and Find Full Text PDF

Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature.

Discov Oncol

January 2025

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.

Monotherapy with anti-programmed cell death protein 1 (PD-1) monoclonal antibody has been approved for the treatment of advanced non-small cell lung cancer with positive programmed cell death-ligand 1 (PD-L1) expression and oncogene wild type, which revealed survival benefit compared with chemotherapy. Nevertheless, certain patients develop rapid progression on anti-PD-1 inhibitor monotherapy. This novel pattern is called hyperprogressive disease (HPD), and the underlying mechanism and molecular characteristics still leaves not clear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!